BIOGENERA will participate in the Bio Europe Spring in Barcelona
Building on the success of EBD Group’s flagship conference, BIO-Europe®, BIO-Europe Spring will bring together more than 3,700 top executives from around the world. More than 20,000 meetings of potential partnerships will take place to connect leaders in academia, start-ups and growing biotechnology companies with forward-looking investors and pharmaceutical companies.
NewCap is chosen as the new investor relations firm for BIOGENERA
È stato siglato un accordo con NewCap, società francese di Investor Relation, la quale si occuperà della gestione delle comunicazioni ufficiali di BIOGENERA SpA a partire dalla quotazione in borsa su Euronext di Parigi.
BIOGENERA participated in the International Congress on Neuroblastoma ANR (Advances in Neuroblastoma Research) held in Amsterdam May 15-18, 2023
The congress was attended by more than 800 researchers from around the World. Preclinical data of BIOGENERA’s new anti-tumor drug BGA002 were presented, and the new Phase I clinical trial for Neuroblastoma that will be initiated in the coming months was also presented. The data attracted great interest and attention.
Thibaud Eckenschwiller has been appointed president of BIOGENERA, May 2023
Il 2 Maggio 2023 l’assemblea dei soci di BIOGENERA ha approvato il bilancio 2022, in questa occasione è stato anche nominato il nuovo Consiglio di Amministrazione (CdA). Il Dott. Thibaud Eckenschwiller è stato nominato Presidente del CdA di BIOGENERA. Il Dott. Eckenschwiller è top manager del settore farmaceutico con ampia esperienza internazionale.
Giacinto d’Ettorre becomes board member of BIOGENERA
Dr. Giacinto d’Ettorre has been appointed as a new board member of BIOGENERA. Dr. D’Ettorre has many years of experience in the pharmaceutical industry at management levels. He currently serves as chief financial officer (CFO) at a leading pharmaceutical company, and previously served as CFO of Europe at SHIRE (now merged into TAKEDA), and CFO of Brazil for ROCHE.
Patent Approval in Argentina
Regarding patents held by BIOGENERA, a patent has been granted outright in Argentina. This brings to a total of 56 fully-owned BIOGENERA patents that are approved outright, covering 46 countries globally, covering the MyGeneraTM platform, the drug BGA002 and five other drug candidates.
The company ComputerShare has been chosen to manage the corporate structure of BIOGENERA.
BIOGENERA has signed an agreement with Computershare Italia, which is part of Computershare Limited, the leading stock transfer company that provides corporate trust, stock transfer and employee stock plan services in numerous countries.
BIOGENERA has reached a new milestone in lung cancer treatment
È stato raggiunto un importante risultato dal Team dei ricercatori di BIOGENERA, riguardante la pubblicazione scientifica di un nuovo articolo sulla prestigiosa rivista internazionale “Cancers”.
MYCN is a key target for cases of High-Risk Neuroblastoma
È stato raggiunto un importante risultato, riguardante la pubblicazione di un articolo sulla prestigiosa rivista internazionale “Cancers” dal titolo “MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment” riguardo la centralità dell’oncogene MYCN nel contesto patologico del neuroblastoma.
Mario Nespoli is the new CFO of BIOGENERA
BIOGENERA has appointed as the company’s new chief financial officer (CFO) Dr. Mario Nespoli, who has many years of experience in the pharmaceutical industry at management levels.
English 
Italian